ClearPoint Neuro Congratulates its Partner AviadoBio on First Patient Treated in its ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations

April 16, 2024

https://www.globenewswire.com/news-release/2024/04/16/2864094/25687/en/ClearPoint-Neuro-Congratulates-its-Partner-AviadoBio-on-First-Patient-Treated-in-its-ASPIRE-FTD-Clinical-Trial-Evaluating-AVB-101-for-Frontotemporal-Dementia-with-GRN-Mutations.html

SOLANA BEACH, Calif., April 16, 2024 (GLOBE NEWSWIRE) — ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today congratulates its partner AviadoBio on treating its first patient in the ASPIRE-FTD Phase 1/2 clinical trial evaluating its investigational gene therapy AVB-101 in people with frontotemporal dementia (FTD) with progranulin (GRN) mutations.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.